26th Sep 2006 10:58
Deltex Medical Group PLC26 September 2006 Deltex Medical Group plc French clinical trial demonstrates utility of CardioQ(TM) in spinal surgery 26 September 2006 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),the UK's leading haemodynamic monitoring company, today highlights thepresentation of a clinical trial undertaken by Dr Payen and colleagues atGrenoble hospital into the use of Deltex Medical's CardioQ monitor. The trialresults were made public at the European Society of Intensive Care Medicine(ESICM) conference in Barcelona earlier today. Patients undergoing spinal surgery are placed face down on the operating table('prone position') throughout the surgery. The prone position can have anadverse effect on the patient's blood circulation ('haemodynamics') andpotentially lead to complications. It is therefore important to be able toidentify and treat any haemodynamic changes in these patients quickly andsafely. The trial results showed that it is possible to monitor patients having spinalsurgery in the prone position effectively and safely using the minimallyinvasive CardioQ. Deltex Medical's chief executive, Andy Hill, commented: "This trial confirms for the first time that the CardioQ works in spinal surgery- where rapid diagnosis and intervention is required to prevent potentiallylife-threatening complications. Multiple randomised trials have demonstratedthat the CardioQ is the only intra-operative haemodynamic monitor which canreduce complications and length of hospital stay." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Nigel ChairmanAndy Hill, Chief ExecutiveEwan Phillips, Finance Director Gavin Anderson & Company 0207 554 1400Deborah WalterMarie CairneyJodie Reilly Charles Stanley Securities 020 7149 6457Philip Davies Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQ which have repeatedly:- • Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • Proved that the CardioQ works in a wide range of surgical procedures • Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Deltex Medical